United States Dermatology Drugs Market to garner hefty returns by 2022

April 26, 2019

Global dermatology drugs market is anticipated to gain immense momentum in the projected timeframe, according to the latest research available at Market Study Report LLC, report provides extensively data on market share, growth, trends and forecasts for the period 2017-2022.

The skin is a leading indicator of the biological activities that may be going on below the surface. So, if a person feels that his skin is in any way not as healthy as it needs to be, then dermatology treatments can be of great help. Dermatology medications can help in the treatment of a wide range of chronic and acute skin conditions including eczema, psoriasis, and acne among others.

As per the report, given the estimated launch of the possible promising treatments, the market is likely to grow in both atopic dermatitis and psoriasis segments. In terms of geographical development, the United States dermatology drugs market amassed a higher market share as compared to Japan and Europe. The humongous market size can be attributed to the growing adoption of high-priced biologics in the region. Despite the launch and accessibility of numerous biologics, only 10% of the patients are able to access these treatments and the market remains largely underpenetrated.

At present, the global dermatology drugs market is exceedingly fragmented, however, it offers several promising commercial opportunities. The market is observing a significant unmet need for cost-effective and safer treatment options. The report cites that back in 2016, Psoriasis market was valued at nearly USD 6 billion on account of the presence of effective TNF alpha treatments. Moreover, in acne, antibiotics and retinoids are the keystone treatments but the presence of promising candidates in the pipeline including Dermira’s DRM-101 and Foamix’s FMX-101 is what makes this indication profitable.

Request sample copy of this Report@ https://www.marketstudyreport.com/request-a-sample/1695053/

The report also offers a comprehensive analysis of the dermatology drugs market drivers, restraints, and opportunities over the estimated timeline. An conscientious presentation of the market in terms of dermatology key indications, treatment class/marketed drugs, and regional landscape is also briefed in the report to apprise business enterprises with the global market scenario.

The competitive landscape of the global dermatology drugs market comprises of eminent market players such as Valeant Pharmaceuticals, Allergan Plc, Dermira Inc, AnaptysBio, Inc, Aclaris Therapeutics, Inc, Revance Therapeutics, Novan, Inc, Foamix Pharmaceuticals, Sienna Biopharmaceuticals, Sanofi, Pfizer, Galderma, Roviant Sciences, Leo Pharma, and Otsuka Pharmaceuticals among others. The company profiles of these key market players have also been included in the report. The notable growth strategies commonly practiced by these companies involve launching new products and collaborating with other market leaders to innovate and introduce new dermatology drugs that suffice the unmet medical needs of the patients, thereby boosting market size over the forecast timeframe.